Curriculum · Screening (National/International)
Hepatocellular carcinoma surveillance in cirrhosis
What it is
Cirrhosis, from any cause, puts the patient under surveillance for hepatocellular carcinoma. Patients with cirrhosis should undergo ultrasonography screening for HCC every 6 months. The same 6 months is repeated in every place where cirrhosis appears in the material: in chronic hepatitis C, in PSC, and in the general follow-up of cirrhosis itself. The two methods of surveillance to name are regular 6-monthly liver US and AFP measurement.
Causes and risk
The risk factors for HCC are liver cirrhosis, chronic hepatitis B and haemochromatosis.
Hepatitis C rarely causes HCC in the absence of cirrhosis, which is why the surveillance follows the cirrhosis rather than the virus.
Hepatitis B is different, because surveillance may be indicated before cirrhosis. The characteristics associated with an increased risk for HCC in patients with HBV, and therefore indications for surveillance with US every 6 months, are cirrhosis, Asian men over 40 years and Asian women over 50 years, Black patients over 20 years, an elevated ALT level with HBV DNA levels above 10,000 U/mL, and a family history of HCC.
Hereditary hemochromatosis is a genetic disorder of iron regulation and subsequent iron overload, and its possible end-organ damage includes cardiomyopathy, cirrhosis of the liver and hepatocellular carcinoma. Identification of such patients and proper ongoing treatment with phlebotomy may prevent the development of hepatocellular carcinoma.
How it is diagnosed
Screening is US abdomen for a lesion together with serum AFP. Once a lesion is found, the diagnosis is made by CT or MRI, with biopsy if the patient is not cirrhotic. AFP has a second use after treatment, where it is used to monitor tumor recurrence.